yttrium radioisotopes has been researched along with Vomiting in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fusco, F; Gibbs, P; Gray, AM; Love, S; Moschandreas, J; Sharma, RA; Van Hazel, G; Virdee, PS; Wasan, HS; Wolstenholme, J | 1 |
| Devlin, PM; Khan, AJ; Siddiqi, NH | 1 |
| Atassi, B; Benson, AB; Gates, VL; Gupta, R; Lewandowski, RJ; Memon, K; Miller, FH; Mulcahy, MF; Newman, S; Nikolaidis, P; Omary, RA; Riaz, A; Ryu, RK; Salem, R; Sato, KT; Yaghmai, V | 1 |
| Bartolomei, M; Bodei, L; Caracciolo, M; Chinol, M; Cremonesi, M; Grana, C; Mäcke, HR; Paganelli, G; Rocca, P; Zoboli, S | 1 |
| Barone, R; Bouterfa, H; Carlier, P; Chen, T; de Camps, J; Jamar, F; Krenning, EP; Kvols, LK; Labar, D; Mathieu, I; Pauwels, S; Schran, H; Smith, MC; Valkema, R; Walrand, S | 1 |
3 trial(s) available for yttrium radioisotopes and Vomiting
| Article | Year |
|---|---|
Quality of life in the FOXFIRE, SIRFLOX and FOXFIRE-global randomised trials of selective internal radiotherapy for metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Colorectal Neoplasms; Fatigue; Female; Humans; Liver Neoplasms; Male; Middle Aged; Nausea; Quality of Life; Surveys and Questionnaires; Vomiting; Yttrium Radioisotopes | 2020 |
Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study.
Topics: Adult; Aged; Amino Acids; Biomarkers, Tumor; Blood Platelets; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Hemoglobins; Humans; Kidney; Lymphocytes; Male; Maximum Tolerated Dose; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Octreotide; Radiation-Protective Agents; Radiometry; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Renal Insufficiency; Vomiting; Yttrium Radioisotopes | 2003 |
86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion.
Topics: Adult; Aged; Amino Acids; Arginine; Cohort Studies; Cross-Over Studies; Dizziness; Drug Combinations; Female; Humans; Infusions, Intravenous; Kidney; Lysine; Male; Metabolic Clearance Rate; Middle Aged; Neuroendocrine Tumors; Octreotide; Organ Specificity; Radiation Dosage; Radiation Injuries; Radiation-Protective Agents; Radiometry; Radiopharmaceuticals; Tissue Distribution; Tomography, Emission-Computed; Vomiting; Yttrium Radioisotopes | 2003 |
2 other study(ies) available for yttrium radioisotopes and Vomiting
| Article | Year |
|---|---|
Palonosetron--a single-dose antiemetic adjunct for hepatic artery radioembolization: a feasibility study.
Topics: Embolization, Therapeutic; Feasibility Studies; Female; Hepatic Artery; Humans; Isoquinolines; Liver Neoplasms; Male; Middle Aged; Nausea; Palonosetron; Quinuclidines; Retrospective Studies; Serotonin Antagonists; Treatment Outcome; Vomiting; Yttrium Radioisotopes | 2009 |
Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes.
Topics: Abdominal Pain; Aged; Analysis of Variance; Diarrhea; Embolization, Therapeutic; Fatigue; Female; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Nausea; Neuroendocrine Tumors; Retrospective Studies; Survival Rate; Treatment Outcome; Vomiting; Weight Loss; Yttrium Radioisotopes | 2012 |